Diehard Bargain Hunter: Halozyme Therapeutics, Inc. (HALO), Viavi Solutions Inc. (VIAV)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares were trading higher by 1.16 percent ($0.21) at $18.39 a piece in Monday’s session. It had closed the previous session at $18.18. HALO trades with a P/S ratio of 16.08. This is lower than the industry’s 85.73 but higher compared with the wider sector’s 5.08. A low price-to-sales ratio, typically less than 1.0, is considered a good value. . Shares of HALO have uptrended 54.54% in the past three months, while the S&P 500 has moved 44.43% in that time. Halozyme Therapeutics, Inc. (HALO) has a market cap of $2.67 billion and over the last 12 months, Halozyme Therapeutics, Inc. (NASDAQ:HALO) has gone stronger by 46.18%. During the last 52 weeks, the (NASDAQ:HALO) price has been as high as $19.37 and as low as $9.68. Halozyme Therapeutics, Inc. earnings have declined with an annualized rate of -33.1% over the last 5 years.

Halozyme Therapeutics, Inc. (Mean Target Price: $20.6)

The average 1-year price target for Halozyme Therapeutics, Inc. (HALO) — averaging the work of different analysts — reveals a mean PT of $20.6/share. That’s a potential 12.02 increase relative to where Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been trading recently. The current price is seen ranging between $18.05 and $18.48. There are brokerage firms with lower targets than the average, including one setting a price target of $8. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $33.

Halozyme Therapeutics, Inc. (HALO) Consensus Recommendation

The collective rating of 2.3 for Halozyme Therapeutics, Inc. (NASDAQ:HALO) also leans strongly towards the neutral end of the spectrum. Of the 10 analysts surveyed by Reuters that track HALO 2 of them rate its stock a hold. The other 8, though not evenly; between analysts who think you should buy Halozyme Therapeutics, Inc. versus those who think you should sell it. A 7 analysts rate it as either a buy or a strong buy, while1 believe that investors should either steer clear of HALO or, if they already own its stock, sell it.

Is Viavi Solutions Inc. (NASDAQ:VIAV) Cheap From Peers?

Viavi Solutions Inc. (VIAV) pulled off a 1.17 percent gain and now trades for $8.65. VIAV comes in with a P/S ratio of 2.48 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (2.86) and its peers (1.49). Also, it has an estimated price-earnings (P/E) multiple of 17.58 and a trailing 12-month price-earnings (P/E) multiple of 24.57. During the last 52 weeks, the price has been as high as $11.89 and as low as $7.56. Viavi Solutions Inc. (NASDAQ:VIAV) earnings have declined with a quarterly rate of -13.4% over the last 5 years. Shares of VIAV have sank -18.63% in the past three monthswhile the S&P 500 has dropped -23.16% in that time.

Viavi Solutions Inc. (Price Objective: $11.5)

Viavi Solutions Inc. (NASDAQ:VIAV) has a market cap of $1.97 billion and over the last 12 months, VIAV has risen by 10.9%. The average 1-year price target for (VIAV) reveals an average price target of $11.5 per share. That’s a potential 32.95 gain from where (NASDAQ:VIAV) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $9. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $17.

Analyst Thoughts About Viavi Solutions Inc. (NASDAQ:VIAV)

The consensus recommendation — averaging the work of 9 analysts — of 2.3 for Viavi Solutions Inc. (VIAV) points to moderate case. Of the analysts surveyed by Reuters that track Viavi Solutions Inc. 4 of them rate its stock a hold. The other 5 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 5 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NASDAQ:VIAV) or, if they already own its stock, sell it.